Form 4: ATAI Life Sciences N.V. Executive Granted 1,450,000 Stock Options

Chief Operating Officer Gerd Kochendoerfer of ATAI Life Sciences N.V. was granted 1,450,000 stock options on January 2, 2025, vesting over a three-year period.

Summary

• Gerd Kochendoerfer, the Chief Operating Officer of ATAI Life Sciences N.V., was granted 1,450,000 stock options on January 2, 2025.
• The options have an exercise price of $1.60.
• The stock options vest as to 25% on December 3, 2025, and the remaining 75% vests in 36 substantially equal monthly installments thereafter.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock option grant. However, the grant suggests confidence in the executive and the company's future, leading to a slightly positive sentiment.

Positives

• The granting of stock options to the COO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the biotech industry to attract and retain key executives and align their interests with those of shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Pfizer, Johnson & Johnson, and Novartis also use stock options to incentivize their executives.
• The vesting schedule of 25% after one year followed by monthly installments is a common vesting structure.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the COO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates